HemaFus BCR-ABL1(P210) Fusion Gene High Sensitivity Detection Kit (Fluorescent PCR)

Product Description Background

The ABL1 gene has a break in intron 1 or 2 (Figure 2). Ph chromosome or BCR-ABL1 (b2a2 and b3a2) have emerged as the main diagnostic criteria for CML, while ela2 mainly appears in ALL.

 In CML patients, the typical BCR-ABL1 transcript subtypes are b3a2 (55%) and b2a2 (40%); simultaneous expression of both b3a2 and b2a2 occurs in 5% of CML patients. In addition, BCR/ABL1 e19a2 fusion gene is present in very few Ph+ CML patients. Subtype P210 can be found in 30%–50% of adult Ph+ ALL patients and 20%–30% of childhood Ph+ ALL patients. The BCR/ABL1 fusion gene subtype is P190 in 60% of Ph+ ALL patients. 

Tyrosine kinase inhibitors (TKIs), such as imatinib, have been used as first-line drugs to achieve a 10-year survival rate of 85%-90% in CML patients who test positive for BCR-ABL1. Second-generation TKIs, such as nilotinib and dasatinib, have also become the first-line treatment option for CML patients as they can achieve faster and deeper molecular responses in the first-line treatment of CML. ALL patients with positive BCR-ABL1 have a poor prognosis with a 5-year survival rate of < 20%. Therefore, these patients require bone marrow transplantation after 

Features

Simple operation and less time consumption; reliable results and intuitive interpretation; high sensitivity and sample saving.

Detection Process

The e13a2 and e14a2 subtypes of BCR-ABL1 P210 fusion gene are quantitatively detected by fluorescence quantitative PCR. And the detection sensitivity can reach MR4.5.

Ordering Information